Next-generation sequencing for myeloid malignancies
Canadian Hematology Today · 2022
DOI: 10.58931/cht.2022.115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von James A. Kennedy. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Over the past two decades, next-generation sequencing (NGS) has revolutionized our understanding of the pathogenesis of myeloid neoplasms (MNs) and their clinical management. While traditional Sanger sequencing allows for the interrogation of single loci, NGS enables the parallel sequencing of multiple genomic locations, ranging from targeted sets of genes to the entire genome. Initially, NGS was used predominantly in research, where the ability to interrogate large regions of the genome facilitated the discovery of genes recurrently mutated in myeloid malignancies. Soon thereafter, NGS entered the clinical realm where it is now routinely utilized in diagnosis, prognostication and treatment decision-making. However, the broad availability of clinical NGS comes with a unique set of challenges. Hematologists must interpret complex molecular reports and appropriately apply the provided mutational information to their patients’ care in real-time. Consequently, a systematic approach to interpreting NGS reports is crucial; the following will outline one such framework.
Zitieren
APA
Kennedy, J. A. (2022). Next-generation sequencing for myeloid malignancies. Canadian Hematology Today. https://doi.org/10.58931/cht.2022.115
Vancouver
Kennedy JA. Next-generation sequencing for myeloid malignancies. Canadian Hematology Today. 2022. doi:10.58931/cht.2022.115
BibTeX
@article{Kennedy2022,
author = {Kennedy, James A.},
title = {Next-generation sequencing for myeloid malignancies},
journal = {Canadian Hematology Today},
year = {2022},
doi = {10.58931/cht.2022.115}
}
EUVIMED